Clinical Trials Browser

Active not recruiting × Doxorubicin × Genitourinary × Clear all

NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT02420847 2025-11-10

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Phase 1/2 Active not recruiting

Carcinoma, Transitional Cell

NCT00479128 2025-10-28

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT00945009 2025-05-31

Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

Phase 3 Active not recruiting

249 enrolled 14 charts

Beckwith-Wiedemann Syndrome, Wilms Tumor

NCT02710734 2024-12-24

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Phase 2 Active not recruiting

Urothelial Carcinoma of the Bladder

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell